Beacon Equity Issues Technical Trade Alerts on: EPCT, INSM, AMGN, CYBS, KONG, NCOC
EpiCept Corp. (EPCT) shares surged 170% Friday, climbing another 9% to 88 cents Monday morning; the activity follows the company’s announcement that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMEA) has issu
(EMAILWIRE.COM, July 28, 2008 ) DALLAS, Texas - Today’s Trade Alerts include: EpiCept Corp. (Nasdaq: EPCT), Insmed Inc. (Nasdaq: INSM), Amgen Inc. (Nasdaq: AMGN), CyberSource Corp. (Nasdaq: CYBS), KongZhong Corp. (Nasdaq: KONG), and National Coal Corp. (Nasdaq: NCOC).
“EpiCept Corp. (EPCT) shares surged 170% Friday, climbing another 9% to 88 cents Monday morning; the activity follows the company’s announcement that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMEA) has issued a positive opinion regarding the marketing authorization for Ceplene (histamine dihydrochloride). EpiCept, a specialty pharmaceutical company, focuses on the development of pharmaceutical products for the treatment of cancer and pain. Its lead oncology product candidate is Ceplene, which is used for the treatment of acute myeloid leukemia...
“Ceplene, to be administered in conjunction with low-dose interleukin-2 (IL-2), is for the remission maintenance and prevention of relapse in adult patients with Acute Myeloid Leukemia (AML) in first remission…
”The positive opinion was issued following a request made by EpiCept to have the initial negative opinion of March 2008 re-examined by CHMP. Ceplene, designated as an orphan medicinal product, is entitled to 10 years of marketing exclusivity in the EU...”
“Insmed Inc. (INSM) shares rose 4% to 80 cents just after Monday’s opening bell. Insmed, a development stage company, engages in the development of recombinant protein drugs…
“Insmed recently announced it will host a conference call Friday, August 8 at 8:30 a.m. ET, to discuss its results for the second quarter 2008. Insmed intends to issue its quarterly financial results press release before the market opens on August 8…
“The company also announced Geoffrey Allan, Ph.D., CEO of Insmed, will present at IBC's 13th Annual Drug Discovery and Development of Innovative Therapeutics Thursday, August 7, 2008, at 9:25 a.m. ET…”
Investors can view all of the TraderNotes and investment articles for free by visiting:
http://www.beaconequity.com/m
Join the fastest growing investor community at:
http://www.stocknetworkonline.com/
BeaconEquity.com’s Market News is one of the fastest growing small cap blogs in the investment community. Beacon is the authority on research in the small cap sector, and our analysts strive each day to find the stocks that are poised to be the biggest movers before the rest of the market is aware of them.
We encourage investors to subscribe to our FREE newsletter filled with daily trading ideas by visiting: http://www.BeaconEquity.com/m
BeaconEquity.com is one of the industry’s largest small cap research providers. Beacon strives to provide a balanced view of many promising small cap companies that would otherwise fall under the radar of the typical Wall Street investor. We provide investors with an excellent first step in their research and due diligence by providing daily trading ideas, and consolidating the publicly available information available on them. For more information on Beacon Research, please visit: http://www.BeaconEquity.com
Beacon Equity Research Disclosure
The analysts contributing to this report do not hold any shares of EpiCept Corporation (Nasdaq: EPCT). Additionally, the analysts contributing to this report certify that the views expressed herein accurately reflect the analysts' personal views as to the subject securities and issuers. The analyst(s) writing this report recognize and aspire to all of the CFA Institute Guidelines for Independent Research. Beacon Equity Research (“Beacon”) certifies that no part of the analysts' compensation was, is, or will be, directly or indirectly, related to the specific recommendation or views expressed by the analysts in the report. This report is based on data obtained from sources we believe to be reliable, but is not guaranteed as to accuracy and does not purport to be complete. As such, the report should not be construed as advice designed to meet the particular investment needs of any investor. Any opinions expressed herein are subject to change.
Source: BeaconEquity.com
Beacon Equity Research
Jeff Bishop, (469)-252-3505
press@beaconequity.com
“EpiCept Corp. (EPCT) shares surged 170% Friday, climbing another 9% to 88 cents Monday morning; the activity follows the company’s announcement that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMEA) has issued a positive opinion regarding the marketing authorization for Ceplene (histamine dihydrochloride). EpiCept, a specialty pharmaceutical company, focuses on the development of pharmaceutical products for the treatment of cancer and pain. Its lead oncology product candidate is Ceplene, which is used for the treatment of acute myeloid leukemia...
“Ceplene, to be administered in conjunction with low-dose interleukin-2 (IL-2), is for the remission maintenance and prevention of relapse in adult patients with Acute Myeloid Leukemia (AML) in first remission…
”The positive opinion was issued following a request made by EpiCept to have the initial negative opinion of March 2008 re-examined by CHMP. Ceplene, designated as an orphan medicinal product, is entitled to 10 years of marketing exclusivity in the EU...”
“Insmed Inc. (INSM) shares rose 4% to 80 cents just after Monday’s opening bell. Insmed, a development stage company, engages in the development of recombinant protein drugs…
“Insmed recently announced it will host a conference call Friday, August 8 at 8:30 a.m. ET, to discuss its results for the second quarter 2008. Insmed intends to issue its quarterly financial results press release before the market opens on August 8…
“The company also announced Geoffrey Allan, Ph.D., CEO of Insmed, will present at IBC's 13th Annual Drug Discovery and Development of Innovative Therapeutics Thursday, August 7, 2008, at 9:25 a.m. ET…”
Investors can view all of the TraderNotes and investment articles for free by visiting:
http://www.beaconequity.com/m
Join the fastest growing investor community at:
http://www.stocknetworkonline.com/
BeaconEquity.com’s Market News is one of the fastest growing small cap blogs in the investment community. Beacon is the authority on research in the small cap sector, and our analysts strive each day to find the stocks that are poised to be the biggest movers before the rest of the market is aware of them.
We encourage investors to subscribe to our FREE newsletter filled with daily trading ideas by visiting: http://www.BeaconEquity.com/m
BeaconEquity.com is one of the industry’s largest small cap research providers. Beacon strives to provide a balanced view of many promising small cap companies that would otherwise fall under the radar of the typical Wall Street investor. We provide investors with an excellent first step in their research and due diligence by providing daily trading ideas, and consolidating the publicly available information available on them. For more information on Beacon Research, please visit: http://www.BeaconEquity.com
Beacon Equity Research Disclosure
The analysts contributing to this report do not hold any shares of EpiCept Corporation (Nasdaq: EPCT). Additionally, the analysts contributing to this report certify that the views expressed herein accurately reflect the analysts' personal views as to the subject securities and issuers. The analyst(s) writing this report recognize and aspire to all of the CFA Institute Guidelines for Independent Research. Beacon Equity Research (“Beacon”) certifies that no part of the analysts' compensation was, is, or will be, directly or indirectly, related to the specific recommendation or views expressed by the analysts in the report. This report is based on data obtained from sources we believe to be reliable, but is not guaranteed as to accuracy and does not purport to be complete. As such, the report should not be construed as advice designed to meet the particular investment needs of any investor. Any opinions expressed herein are subject to change.
Source: BeaconEquity.com
Beacon Equity Research
Jeff Bishop, (469)-252-3505
press@beaconequity.com
Contact Information:
Beacon Equity Research
Jeff Bishop
Tel: (469)-252-3505
Email us
This is a press release. Press release distribution and press release services by EmailWire.Com: http://www.emailwire.com/us-press-release-distribution.php.
Beacon Equity Research
Jeff Bishop
Tel: (469)-252-3505
Email us
This is a press release. Press release distribution and press release services by EmailWire.Com: http://www.emailwire.com/us-press-release-distribution.php.
|
Private Equity, Angel Investing
Equity Alliance / Private Equity, Angel Investing, / IPO, Venture Capital & IR services / Equity Alliance International Equityallianceir.com Penny Stocks to Watch Sign up for hot penny stock picks Gains of 500%+ possible! Premiumstockpicks.com/landing/ Your text Ads & PR Text Ads plus unlimited press releases, One release featured/Day for only $575 per month. Read more on Text Ads & PR Your text Ads Here! Text Ads are only $289 per month. Ads are placed same day. More on Text Ads Advertising |